Myriad Genetics (MYGN) analyst forecast and price target
Analyst forecast
Consensus of 9 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Stephens & Co. | Maintained | Equal-Weight | $3.00 from $5.00 | Aug 18, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $3.00 from $5.50 | Aug 3, 2026 |
| TD Cowen | Maintained | Hold | $4.00 from $6.00 | Jul 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $5.50 from $6.00 | May 6, 2026 |
| TD Cowen | Maintained | Hold | $6.00 from $7.00 | May 6, 2026 |
| UBS | Maintained | Neutral | $6.00 from $8.00 | Feb 24, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $6.00 from $6.50 | Feb 24, 2026 |
| Piper Sandler | Maintained | Overweight | $8.50 from $9.00 | Nov 11, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $6.50 from $6.00 | Nov 5, 2025 |
| UBS | Maintained | Neutral | $8.00 from $6.00 | Nov 4, 2025 |
| TD Cowen | Maintained | Hold | $9.00 from $8.00 | Nov 4, 2025 |
| Scotiabank | Downgraded | Sector Outperform → Sector Perform | $6.00 from $20.00 | May 21, 2025 |
| Piper Sandler | Maintained | Overweight | $9.00 from $12.50 | May 15, 2025 |
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $6.00 from $22.00 | May 8, 2025 |
| Raymond James | Maintained | Outperform | $10.00 from $19.00 | May 7, 2025 |
| UBS | Maintained | Neutral | $7.00 from $16.00 | May 7, 2025 |
| Goldman Sachs | Maintained | Buy | $8.00 from $14.00 | May 7, 2025 |
| Goldman Sachs | Maintained | Buy | $14.00 from $18.00 | Apr 17, 2025 |
| Guggenheim | Downgraded | Buy → Neutral | — | Apr 9, 2025 |
| Scotiabank | Maintained | Sector Outperform | $20.00 from $24.00 | Apr 1, 2025 |
Frequently asked questions
What is the price target for MYGN stock?
The average 12-month analyst price target for Myriad Genetics (MYGN) is $3.33, with a high estimate of $4.00 and a low of $3.00, across 3 analysts.
Is MYGN a buy, sell, or hold?
Analysts covering Myriad Genetics currently average a Hold rating: 2 buy, 5 hold and 2 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for MYGN?
The average price target of $3.33 implies 3.04% upside from the last price of $3.24.
What is the latest analyst rating on MYGN?
On Aug 18, 2026, Stephens & Co. maintained Myriad Genetics at Equal-Weight with a price target of $3.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.